These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9789122)

  • 41. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
    Lissoni P; Pittalis S; Rovelli F; Zecchini S; Casati M; Tremolada M; Pelizzoni F
    J Biol Regul Homeost Agents; 1996; 10(1):27-30. PubMed ID: 9049779
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
    Lissoni P; Barni S; Ardizzoia A; Olivini G; Brivio F; Tisi E; Tancini G; Characiejus D; Kothari L
    J Biol Regul Homeost Agents; 1993; 7(4):121-5. PubMed ID: 8023699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer.
    Maestroni GJ
    Adv Exp Med Biol; 1999; 467():217-26. PubMed ID: 10721059
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy with low-dose interleukin-2 in association with melatonin as salvage therapy for metastatic soft tissue sarcomas.
    Lissoni P; Barni S; Ardizzoia A; Tancini G
    Oncol Rep; 1997; 4(1):157-9. PubMed ID: 21590033
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
    Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Meregalli S; Fossati V; Fumagalli L; Brivio F; Tancini G
    Oncology; 1995; 52(3):243-5. PubMed ID: 7715908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients.
    Lissoni P; Ardizzoia A; Barni S; Paolorossi F; Tancini G; Meregalli S; Esposti D; Zubelewicz B; Braczowski R
    Oncol Rep; 1995 Sep; 2(5):871-3. PubMed ID: 21597833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
    Lissoni P; Brivio F; Barni S; Tancini G; Cattaneo G; Archili C; Conti A; Maestroni GJ
    Anticancer Res; 1990; 10(6):1759-61. PubMed ID: 2285255
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
    Lissoni P; Pittalis S; Rovelli F; Vigorè L; Roselli MG; Brivio F
    J Biol Regul Homeost Agents; 1995; 9(2):63-6. PubMed ID: 9127635
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The importance of spirituality in supportive care.
    Messina G; Anania S; Bonomo C; Veneroni L; Andreoli A; Mameli F; Ortolina C; De Fabritiis P; Gaffuri M; Imbesi F; Moja E
    Int J Yoga; 2011 Jan; 4(1):33-8. PubMed ID: 21654973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Melatonin as biological response modifier in cancer patients.
    Neri B; de Leonardis V; Gemelli MT; di Loro F; Mottola A; Ponchietti R; Raugei A; Cini G
    Anticancer Res; 1998; 18(2B):1329-32. PubMed ID: 9615811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
    Lissoni P; Barni S; Ardizzoia A; Brivio F; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1992; 6(4):132-6. PubMed ID: 1296454
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state.
    Lissoni P; Paolorossi F; Ardizzoia A; Barni S; Chilelli M; Mancuso M; Tancini G; Conti A; Maestroni GJ
    J Pineal Res; 1997 Aug; 23(1):15-9. PubMed ID: 9379341
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
    Lissoni P; Tisi E; Brivio F; Ardizzoia A; Crispino S; Barni S; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1991; 5(4):154-6. PubMed ID: 1803863
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modulation of cytokine production from TH2-lymphocytes and monocytes by the pineal neurohormone melatonin.
    Lissoni P; Pittalis S; Rovelli F; Roselli M; Ardizzoia A
    Oncol Rep; 1996 May; 3(3):541-3. PubMed ID: 21594408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study.
    Yan JJ; Shen F; Wang K; Wu MC
    Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):183-6. PubMed ID: 14607735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression.
    Brivio F; Fumagalli L; Fumagalli G; Pescia S; Brivio R; Di Fede G; Rovelli F; Lissoni P
    In Vivo; 2010; 24(2):239-41. PubMed ID: 20364003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status.
    Lissoni P; Brivio F; Ardizzoia A; Tancini G; Barni S
    Tumori; 1993 Dec; 79(6):401-4. PubMed ID: 8171739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer.
    Lissoni P; Rovelli F; Brivio F; Zago R; Colciago M; Messina G; Mora A; Porro G
    In Vivo; 2009; 23(1):171-5. PubMed ID: 19368145
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of cytokine-induced hypotension in cancer patients by the pineal hormone melatonin.
    Lissoni P; Pittalis S; Ardizzoia A; Brivio F; Barni S; Tancini G; Pelizzoni F; Maestroni GJ; Zubelewicz B; Braczkowski R
    Support Care Cancer; 1996 Jul; 4(4):313-6. PubMed ID: 8829312
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preoperative neuroimmunotherapy with subcutaneons low-dose interleukin-2 and melatonin in patients with gastrointestinal tumors - its efficacy in preventing surgery-induced lymphocytopenia.
    Brivio F; Lissoni P; Fumagalli L; Brivio O; Lavorato F; Rescaldani R; Conti A; Roselli M; Maestroni G; Barni S
    Oncol Rep; 1995 Jul; 2(4):597-9. PubMed ID: 21597783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.